3M-052 联合抑制性抗 TNFR2 协同抑制结肠癌进展

A CRC mouse model was established and divided into four treatment groups: the control group, the 3M-052 group, the anti-TNFR2 group, and the MT group. Tumour growth was monitored every three days. Flow cytometry was used to analyse the levels of CD8+ T cells and regulatory T cells (Tregs) in tumour tissue, as well as the differentiation of central memory T cells (Tcm) in the tumor-draining lymph nodes (TdLNs).

The results revealed that the combination therapy MT promoted CD8+ T cell infiltration and reduced Tregs level within the tumor, effectively suppressed colon cancer growth in mice, and induced long-term syngeneic tumor control by enhancing the differentiation of Tcm in TdLNs. Compared with monotherapy, combination therapy MT demonstrated a superior capacity to induce the differentiation of central memory CD8+ and CD4+ T cells in TdLNs, an effect that appears to be primarily mediated by 3M-052. DISCUSSION: This study demonstrates that the combination of 3M-052 and the anti-TNFR2 antibody exerts a synergistic effect, effectively inhibiting CRC progression and inducing long-term immune memory. Overall, these findings support the view that MT combination therapy represents a potentially effective strategy.